07 December 2023

In the latest issue of the New England Journal of Medicine (NEJM), Senior Professor Johnny Ludvigsson delves into the strides and challenges confronting type 1 diabetes research. A select few researchers have been invited to write an editorial in NEJM, making this a prestigious acknowledgment. "It's an honor and nice that LiU is also recognized," notes Johnny.

Johnny Ludvigsson. Johnny Ludvigsson. John Karlsson

To write an editorial article in the New England Journal of Medicine (NEJM), one of the world's foremost medical journals, is a rare opportunity for Swedish researchers. Johnny Ludvigsson received the invitation to contribute to the journal in conjunction with the publication of two original articles by other type 1 diabetes researchers in NEJM on December 7.

In the December issue, Johnny Ludvigsson reflects on the progress made and the challenges facing type 1 diabetes research.

"It can be perceived as a recognition of how the world's most prestigious medical scientific journal views my position as a diabetes researcher. In that way, it feels honorable and nice that Linköping University is also visible. Additionally, it feels good to have a say in a very important issue that can influence decision-makers, authorities, healthcare, and researchers", says Johnny.

Beta cells and immune therapy drugs

In the article "Immune Interventions at Onset of Type 1 Diabetes — Finally, a Bit of Hope" Ludvigsson criticizes the dominant focus on blood sugar control and advocates for an increased interest in preserving dying pancreatic beta cells. In simpler terms, beta cells are crucial insulin-producing cells in the pancreas, and their preservation is key to addressing the root cause of type 1 diabetes.

The article discusses a Phase III study led by Eleanor L. Ramos et al, demonstrating the success of teplizumab (an immune therapy drug) – an immune intervention. The randomized, double-blinded, placebo-controlled study included patients aged 8-17 and showed significantly higher stimulated C-peptide levels in those treated with teplizumab, 1.5 years after treatment. C-peptide is a marker of insulin production, and shows the body's ability to produce insulin.

Balancing side effects with treatment success

While acknowledging the discomfort and side effects associated with teplizumab, Ludvigsson emphasizes the importance of preserving beta cells. The editorial notices that the FDA and other regulatory bodies in these studies have accepted the preservation of beta cells as the primary goal, and underlines that it is important that the authorities also in future trials accept this assessment of diabetes interventions.

Ludvigsson delves into other promising treatments like golimumab and baricitinib, discussing their potential to preserve beta cells. The article highlights a Phase II study with baricitinib, a JAK inhibitor, showing significant preservation of C-peptide and suggesting alternative treatment paths. JAK inhibitors are a type of medication that can affect the immune system, and their potential role in preserving beta cells adds a new dimension to the treatment of type 1 diabetes.

Call for early intervention

The article concludes by emphasizing the critical importance of offering treatments at the onset of type 1 diabetes. Ludvigsson acknowledges the challenges these treatments may pose but argues that they hold the promise of partial remission and, ultimately, a cure. The article calls for increased research efforts to improve these interventions, establish optimal combinations, inclusion criteria, treatment duration, and long-term outcomes.

Read more

For further details, read the full editorial article by Senior Professor Johnny Ludvigsson in the December 7 issue of the New England Journal of Medicine (NEJM).


More news about Johnny's research

teenage girl using insulin.

Antiviral drugs could preserve capacity to produce insulin in type 1 diabetes patients

Antiviral drug treatment could preserve the remaining capacity to release insulin in children recently diagnosed with type 1 diabetes, according to a new study by Scandinavian researchers.

Older man engaged in a discussion.

Gut flora disrupted many years before onset of child rheumatism

A study by researchers from LiU and the University of Florida is the first study to point to the role of early life gut flora in developing child rheumatism, the cause of which is not yet known.

Yawning baby.

Researching gut bacteria as protection against disease

Did the bacteria in your guts when you were a baby impact your risk of future disease? We have talked to researcher studying whether diseases such as type 1 diabetes and allergy could be prevented by promoting the right bacteria early in life.

Latest news from LiU

young man taking a break from running.

Physical fitness in adolescence linked to less atherosclerosis later

Men who were physically fit when they were young had a lower risk of atherosclerosis almost 40 years later. These findings suggest that atherosclerosis is one of the mechanisms behind the link between physical fitness and cardiovascular disease.

Two female student, dissasembling an Ikea product.

Students disassemble Ikea products

This is part of a research project in which LiU students get to collaborate with the Swedish furniture giant. The students document possibility of repairing, replacing and reusing.

A smiling man in a blue jacket and a lightblue shirt

Innovative semiconductor research from LiU to Silicon Valley

LiU alumnus and doctoral student Ivan Martinovic swapped Swedish winter for a warmer climate and headed for Silicon Valley.  He represents the LEAD company Polar Light Technologies in Berkeley SkyDeck’s sought-after accelerator programme.